Open-Label Extension Study to Pioneer Study 6058-SCD-101
Trial details
- Registry ID
- NCT07401823
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as FTX-6058
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Open-Label Extension Study to Pioneer Study 6058-SCD-101NCT07401823 | Fulcrum Therapeutics | Phase 2 | Terminated | 2026-06-04Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |